Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims
The patient portal interface and communication tools are central to the FeelGood experience, especially for ongoing support and titration management
Everything weve been doing for the last five, six years when it comes to reducing sodium, fat, sugar, reducing the portions of our products, adding some new cooking methods to our snacks, those are all very positive trends that will help us pivot the portfolio if needed in the future
Watch her full presentation here #WorldPsoriasisDay #StopTheDominoEffect #WPD2025 #Comorbidities To view or add a comment, sign in As a doctor, Ive often seen patients walk into the clinic feeling perfectly fine only to discover dangerously high blood pressure levels
the serious ones gallbladder and pancreatitis signals are not dose-titration issues and warrant clinical attention whenever they appear, at any dose
Indeed, studies indicate that the majority of Americans have heard of these injectables and more than half agree that they are good options for individuals with obesity or other weight-related health conditions
